Published: April 22, 2024
Background: The recent usage of immunotherapy combined with chemoradiotherapy has improved survival in advanced non-small cell lung cancer (NSCLC) patients. However, determining the most effective therapy combination remains a topic debate. Research suggests immune checkpoint inhibitors (ICIs) post-chemoradiotherapy enhance survival, but impact concurrent ICIs during on rapid disease progression is unclear. This meta-analysis aims to assess effectiveness and safety radiotherapy or cancer. Methods: We searched PubMed, Embase, Cochrane Library, Web Science for relevant studies, extracting data overall response rate (ORR), progression-free (PFS), (OS), adverse events (AEs). Results: analysis included ten studies 490 participants. Stage III NSCLC ORR was 81.8%, while IV 39.9%. One-year PFS OS were 68.2% 82.6%, compared 27.9% 72.2% IV. Common anemia (46.6%), nausea (47.6%), rash (36.4%), radiation pneumonitis (36.3%). Conclusions: Our shows are safe NSCLC, particularly stage patients at risk before starting after chemoradiotherapy. findings support further phase trials. review protocol registered PROSPERO (CRD42023493685) detailed NIHR HTA programme website.
Language: Английский